Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw.
about
Chronic iron deficiency as an emerging risk factor for osteoporosis: a hypothesisNational Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges.Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives.Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice.Criteria for the prescription of oral bisphosphonates for the treatment of osteoporosis in a series of women referred for tooth extractionDoes estrogen play a role in response to adjuvant bone-targeted therapies?Adverse effects of bisphosphonates: implications for osteoporosis management.Monitoring pharmacological therapy for osteoporosis.Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone.Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.Safety of long-term bisphosphonate therapy for the management of osteoporosis.Important aspects concerning alendronate-related osteonecrosis of the jaws: a literature review.Considerations regarding adherence of anti-osteoporosis therapy.Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC).Circulating markers of bone turnover.Safety and efficacy of denosumab in osteoporotic hemodialysed patients.The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club.Antiresorptives: Safety Concerns-Clinical Perspective.In vivo therapeutic efficacy of TNFα silencing by folate-PEG-chitosan-DEAE/siRNA nanoparticles in arthritic mice.A highly sensitive electrochemical biosensor based on AuNP-modified gold electrodes for selective determination of serum levels of crosslaps.Bisphophonates in CKD patients with low bone mineral density.
P2860
Q26825199-088CE0C1-9619-4277-9CAE-0053A31B425AQ33572610-3B3FE11F-7876-4C55-BC50-B487BA644707Q33702810-8BF49D61-631E-492D-AD60-6DF21AD5572CQ33966587-ECDDBED1-2418-4291-A132-7371D37675B1Q36331967-8D3FD3C7-1EEE-4EAB-95A6-88157B1B5C3FQ36491529-C2AD8D0C-15E1-48E5-BE2D-C2B729926F52Q37246255-B38979BD-85D2-4485-9ED8-57025B816E95Q37689559-8F75CB05-F865-47CF-B440-DB0BD8ACAA3CQ37800179-0B7E38E1-CDF6-456C-A9DB-3976D4533A35Q37862933-CAE5E46E-311D-43E0-8BE3-E4514B2975D4Q37866764-68BC4AF5-6FAC-48F0-A558-2837FA154264Q38164436-D13616F7-C80F-4BEF-A2EB-EDCB668BF7B7Q38294766-C4152EC2-86E2-432C-851E-C8CF2A688D6BQ38970807-5209728B-CF78-485E-8ECA-E6261C6859B7Q39304775-4B37D105-B457-4F64-A0EF-7FF3040B8780Q39618928-20C47775-829E-489A-9403-CFFB8F38D261Q40828040-A4D88F7B-444D-4D55-BF61-629A4CF060ABQ48134286-D8052363-8381-4880-9DB6-67547ED56782Q49387533-C65C165D-2089-454D-8D4A-BEB57D843CACQ53056451-764ABC89-B839-4672-BD1D-73C01EDB11CEQ54313739-94383A73-32BC-4F75-BDD7-74178C146752
P2860
Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Assessing the clinical utility ...... k of osteonecrosis of the jaw.
@en
Assessing the clinical utility ...... k of osteonecrosis of the jaw.
@nl
type
label
Assessing the clinical utility ...... k of osteonecrosis of the jaw.
@en
Assessing the clinical utility ...... k of osteonecrosis of the jaw.
@nl
prefLabel
Assessing the clinical utility ...... k of osteonecrosis of the jaw.
@en
Assessing the clinical utility ...... k of osteonecrosis of the jaw.
@nl
P356
P1476
Assessing the clinical utility ...... k of osteonecrosis of the jaw.
@en
P2093
Paul D Miller
Sanford Baim
P304
P356
10.1359/JBMR.090203
P577
2009-04-01T00:00:00Z